Hubei Biocause Heilen Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022

Hubei Biocause Heilen Pharmaceutical Co Ltd is a China-based company mainly engaged in the research, development, production and sales of chemical Active Pharmaceutical Ingredients (API) and preparation products. The Company's products can be divided into non-steroidal anti-inflammatory, cardiovascular and anti-tumor. The API products include Ibuprofen, D-Ibuprofen, Torasemide, Milrinone, Abiraterone Acetate, Granisetron Hydrochloride, Fludarabine Phosphate and others. The preparation products include Ibuprofen Granules, Ibuprofen Tablets, Ibuprofen Pseudoephedrine Tablets, Oxaprozin Enteric Coated Tablets, Oxaprozin Enteric Coated Capsules, Torasemide Tablets and others. The Company's products are exported to India, the United States, the European Union, South Korea and other countries.